NCT00320073View on ClinicalTrials.gov

Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

January 31, 2010

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

erlotinib hydrochloride

75 mg to 150mg

DRUG

pemetrexed disodium

Pemetrexed is administered intravenously over 10 minutes, every 21 days

DRUG

vinflunine

Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days

Trial Locations (1)

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT00320073 - Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter